Registered Tanzania · TMDA

TETRANOR 25

Anhydrous Glucose Up to 1 g,Oxytetracycline 250 mg/6 mL

TAN 26 VM 0344 Powder for Oral solution blood and blood forming organs INN generic

What it does

Glucose is a simple sugar that provides energy to the body.

Commonly used for: low blood sugar (hypoglycemia), energy supplement

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
TAN 26 VM 0344
Registration date
2026-06-26
Expiry date
2031-06-25
Status
Registered/Compliant
Active ingredient
Anhydrous Glucose Up to 1 g,Oxytetracycline 250 mg/6 mL
Strength
-
Pack size
-
Therapeutic class
-
ATC class (WHO)
B05CX - Other irrigating solutions
RxNorm RxCUI
4850
Applicant / LTR
JUBAILI AGROTEC LIMITED
Country of origin
CHINA

Source: Tanzania Medicines and Medical Devices Authority · fetched 2026-07-06 03:14:20 · updated 2026-10-19 03:00:45

Drug Interactions

8
Check interactions

Pharmacodynamic Warnings

Oxytetracycline appears in TABLE 1: Drugs that cause hepatotoxicity

Severe (1)

Tetracyclines - decreases absorption

Strontium is predicted to decrease the absorption of tetracyclines. Avoid. Theoretical Sucralfate

Severe Theoretical

Moderate (3)

Lithium - increases risk of lithium toxicity

Tetracyclines are predicted to increase the risk of lithium toxicity when given with lithium. Avoid or adjust dose.

Moderate Anecdotal

Tetracyclines - decreases concentration

Fosphenytoin is predicted to decrease the concentration of tetracyclines (doxycycline). Adjust dose.

Moderate Theoretical

Tetracyclines - decreases exposure

Rifampicin modestly decreases the exposure to tetracyclines (doxycycline). Adjust dose.

Moderate Study

Unknown (4)

Tetracyclines - decreases exposure

Mitotane is predicted to decrease the exposure to tetracyclines (eravacycline). Adjust eravacycline dose, p. 625.

Unknown Study

Tetracyclines - decreases exposure

Rifampicin is predicted to decrease the exposure to tetracyclines (eravacycline). Adjust eravacycline dose, p. 625.

Unknown Study

Tetracyclines - decreases exposure

St John's wort is predicted to decrease the exposure to tetracyclines (eravacycline). Adjust eravacycline dose, p. 625.

Unknown Theoretical

Tetracyclines - decreases absorption

Oralzincispredictedtodecreasetheabsorptionof tetracyclines.Separateadministrationby2to3hours. oTheoretical https://www.facebook.c (Books-Courses-Medic

Unknown Theoretical

Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: class

Disclaimer: This information is sourced from Tanzania Medicines and Medical Devices Authority (Tanzania). Always consult a qualified healthcare professional before using any medication.

About glucose

Glucose is a simple sugar that provides energy to the body.

What it treats

  • low blood sugar (hypoglycemia)
  • energy supplement

How it works

Glucose quickly raises blood sugar levels, providing immediate energy.

Who it's for

People who need quick energy, especially those with low blood sugar.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

About oxytetracycline

Oxytetracycline is an antibiotic used to treat various bacterial infections.

What it treats

  • bacterial infections
  • acne
  • respiratory infections
  • urinary tract infections

How it works

It works by stopping the growth of bacteria, helping to eliminate the infection.

Who it's for

It is for adults and children over the age of 12 who have specific bacterial infections.

Drug class

Tetracyclines

Cautions

  • • Avoid use with other medications that can harm the liver.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: Glucose

BNF-referenced

Glucose is a simple sugar and a vital carbohydrate that serves as the primary energy source for human cells. It is essential for various metabolic processes, providing energy through glycolysis and subsequent pathways. Glucose is utilized by nearly all tissues and plays a crucial role in maintaining energy homeostasis in the body. It can be administered orally or intravenously and is commonly used in clinical settings for fluid and electrolyte management.

Indications

  • Fluid and electrolyte imbalances
  • Hypoglycemia
  • Nutritional supplementation
  • Diabetic emergencies

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing guidelines.

Adults: The dosage varies based on the clinical condition and specific formulation used. For intravenous administration, consult product literature for precise dosing.

Mechanism of action

Glucose supplies energy to tissues by undergoing glycolysis, which begins with its phosphorylation by hexokinase to form glucose 6-phosphate. This activates glucose for breakdown, ultimately generating ATP and NADH. The aerobic metabolism of glucose can yield up to 36 ATP molecules. Glucose also serves as a precursor for other biomolecules and regulates various physiological processes including gene transcription and hormone secretion.

Pharmacodynamics

Glucose is an obligatory energy source for cellular activities and plays a significant role in metabolic signaling. It is oxidized to yield energy through glycolysis, the citric acid cycle, and oxidative phosphorylation. Glucose can be converted into fat for energy storage and is stored as glycogen in the liver and muscles. Its administration increases blood glucose levels and stimulates insulin secretion, particularly through oral routes that activate gut incretin hormones.

Pharmacokinetics

Glucose is rapidly absorbed from the gastrointestinal tract or directly into the bloodstream when administered intravenously. It is distributed widely throughout the body and metabolized primarily in tissues requiring energy. The body maintains glucose homeostasis through regulatory mechanisms involving insulin and glucagon. Excess glucose can be stored as glycogen or converted to triglycerides for long-term energy storage.

Adverse effects

  • Hyperglycemia
  • Increased osmolarity
  • Fluid overload
  • Electrolyte imbalances

Interactions

  • Insulin - may require dose adjustments

Precautions

  • Use with caution in patients with diabetes mellitus
  • Monitor blood glucose levels in patients receiving parenteral glucose
  • Adjust dosage in renal impairment

Pregnancy

Glucose is generally considered safe in pregnancy; however, monitoring is advised, especially in diabetic patients.

Breast-feeding

Glucose is considered safe during breastfeeding, as it is a natural sugar found in breast milk.

Storage

Store at room temperature, away from light. Avoid freezing.

Formulations

  • Glucose 5% solution for infusion
  • Glucose 10% solution for infusion
  • Glucose 0.9% solution for injection
  • Glucose sodium chloride combination solutions
BNF 85 (British National Formulary) p.1173 BNF for Children 2019-2020 p.633 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: Oxytetracycline

BNF-referenced

Oxytetracycline is a broad-spectrum antibiotic belonging to the tetracycline class. It is effective against a variety of bacterial infections, including those caused by Chlamydia, Rickettsia, and Mycoplasma. This medication works by inhibiting protein synthesis in bacteria, making it a vital option in treating susceptible infections. Its use is cautioned in pediatric populations due to potential adverse effects on bone and dental development.

Indications

  • Bacterial infections (e.g. Chlamydia, Rickettsia, Mycoplasma)
  • Acne
  • Prophylaxis of asymptomatic meningococcal carrier state (not recommended)

Dosage

Adults: For adult patients, the typical dosage of oxytetracycline for susceptible infections is 100 mg twice daily for 5 days. For other conditions, such as acne, the dosage may be 500 mg twice daily, usually for a duration of 6 to 12 weeks, with the possibility of repeating the course intermittently.

Mechanism of action

Oxytetracycline exerts its antibacterial effects by binding to the 30S ribosomal subunit of bacteria, inhibiting the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This action prevents the synthesis of proteins essential for bacterial growth and replication, leading to the bacteriostatic effect of the drug.

Pharmacodynamics

The pharmacodynamics of oxytetracycline involve its ability to inhibit bacterial protein synthesis, which is critical for the growth and reproduction of bacteria. The drug demonstrates a broad spectrum of activity against both Gram-positive and Gram-negative organisms, as well as some atypical pathogens. Its effectiveness can be influenced by the presence of tetracycline resistance mechanisms in certain bacterial strains.

Pharmacokinetics

Oxytetracycline is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring approximately 1-2 hours after oral administration. It has a relatively long half-life of about 8-10 hours, allowing for twice-daily dosing. The drug is widely distributed in body tissues and fluids, including the liver, kidneys, and lungs, but is less effective in central nervous system infections due to limited penetration. It is primarily excreted via urine, and dosage adjustments may be necessary in patients with renal impairment.

Contra-indications

  • Children under 12 years due to deposition in growing bone and teeth, causing staining and occasionally dental hypoplasia

Adverse effects

  • Gastrointestinal disturbances
  • Photosensitivity
  • Dental discoloration
  • Hepatotoxicity
  • Renal impairment
  • Skin reactions including rash and urticaria
  • Ataxia
  • Hearing impairment
  • Colitis
  • Systemic lupus erythematosus exacerbation

Interactions

  • Antacids and supplements containing calcium, magnesium, or iron may reduce absorption
  • Oral contraceptives may be less effective
  • Other tetracyclines
  • Warfarin (may increase anticoagulant effect)

Precautions

  • Use with caution in patients with renal impairment
  • Monitor for hepatic toxicity in long-term use
  • Patients should be advised to avoid excessive sunlight exposure
  • Discontinue if systemic lupus erythematosus develops or worsens

Pregnancy

Oxytetracycline is contraindicated during pregnancy due to potential harm to fetal development, particularly affecting bone and dental health.

Breast-feeding

Use with caution; oxytetracycline is excreted in breast milk and may affect the infant's dental health.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

  • Oxytetracycline 250 mg tablets
  • Oxytetracycline oral suspension
  • Oxytetracycline oral solution
BNF 85 (British National Formulary) p.646 BNF for Children 2019-2020 p.389 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: Glucose

PubChem CID 5793

Molecular formula: C6H12O6

Mechanism of action

Glucose supplies most of the energy to all tissues by generating energy molecules ATP and NADH during a series of metabolism reactions called glycolysis. Glycolysis can be divided into two main phases where the preparatory phase is initiated by the phosphorylation of glucose by hexokinase to form glucose 6-phosphate. The addition of the high-energy phosphate group activates glucose for the subsequent breakdown in later steps of glycolysis and is the rate-limiting step. Products end up as substrates for following reactions, to ultimately convert C6 glucose molecule into two C3 sugar molecules. These products enter the energy-releasing phase where the total of 4ATP and 2NADH molecules are generated per one glucose molecule. The total aerobic metabolism of glucose can produce up to 36 ATP molecules. These energy-producing reactions of glucose are limited to D-glucose as L-glucose cannot be phosphorylated by hexokinase. Glucose can act as precursors to generate other biomolecules such as vitamin C. It plays a role as a signaling molecule to control glucose and energy homeostasis. Glucose can regulate gene transcription, enzyme activity, hormone secretion, and the activity of glucoregulatory neurons. The types, number, and kinetics of glucose transporters expressed depends on the tissues and fine-tunes glucose uptake, metabolism, and signal generation to preserve cellular and whole body metabolic integrity. Vascular calcification is a hallmark of type 2 diabetes. Glucose stimulates calcification in culture of vascular smooth muscle cells (VSMCs) but the underlying mechanisms remain obscure. We observed that high glucose levels stimulated mouse and human VSMC trans-differentiation into chondrocytes, with increased levels of Sox9, type II collagen, glycosaminoglycan and Runx2 expression, and increased alkaline phosphatase activity and mineralization. These effects were associated with increased expression of IL-1beta, which stimulated alkaline phosphatase and calcification, suggesting that glucose induces chondrocyte differentiation of VSMCs, possibly through IL-1beta activation.

Pharmacodynamics

Blood glucose is an obligatory energy source for humans involved in various cellular activities, and it also acts as a signaling molecule for diverse glucose-sensing molecules and proteins. Glucose undergoes oxidation into carbon dioxide, water, and yields energy molecules in the process of glycolysis and subsequent citric cycle and oxidative phosphorylation. Glucose is readily converted into fat in the body which can be used as a source of energy as required. Under a similar conversion into storage of energy, glucose is stored in the liver and muscles as glycogen. Glucose stores are mobilized in a regulated manner, depending on the tissues' metabolic demands. Oral glucose tablets or injections serve to increase the supply of glucose and oral glucose administration is more effective in stimulating insulin secretion because it stimulates the incretin hormones from the gut, which promotes insulin secretion.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

Molecular reference: Oxytetracycline

PubChem CID 54675779

Molecular formula: C22H24N2O9

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.